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328* Multicentre randomised double blind placebo controlled trial
assessing the effect of weekly risedronate on bone mineral density
in adults with cystic ﬁbrosis
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Low bone mineral density (BMD) is prevalent in adults with cystic ﬁbrosis (CF). The
aim of this study was to assess the efﬁcacy, tolerability and safety of risedronate in
adults with CF and low BMD.
Patients with a lumbar spine (LS) or total hip (TH) BMD Z-score of −1 or less
were randomised to receive risedronate 35mg weekly or identical placebo, and cal-
cium (1 g) + vitamin D3 (800 iu), in addition to their standard multivitamin supplements.
The primary endpoint was the treatment difference in LS BMD at 24 months.
At baseline in the risedronate (n = 17) vs placebo (n = 19) groups, the mean(SD) age was
30.2(12.0) vs 27.8(8.0) years (NS), FEV1 56.0(22.2) vs 53.5(28.5) % predicted (NS),
BMI 22.5(3.2) vs 21.2(3.1) kg/m2 (NS), serum 25-OHD 15.3(6.8) vs 15.7(9.9) ng/ml
(NS), serum PTH 32.2(19.6) vs 31.1(20.7) pg/ml (NS), LS BMD Z-score −1.42(0.53) vs
−1.60(0.48) (NS), and TH BMD Z-score −1.08(0.58) vs −0.78(0.65) (NS), respectively.
By 24 months 9/17 risedronate patients remained on study medication (7 patients
stopped study medication due to bone pain and 1 died) and 12/19 patients in the
placebo group (3 patients withdrew consent and 4 died). After 24 months treatment, the
mean(SD) change in LS and TH BMD in the risedronate vs placebo groups (intention
to treat analysis) was +3.4(5.0) vs +0.6(3.5)% [p = 0.05] and +1.8(5.3) vs −1.8(3.4)%
[p = 0.08].
In conclusion, after two years treatment there was a signiﬁcant increase in lumbar spine
BMD with weekly risedronate compared to placebo. Strategies to reduce the incidence
of bone pain following bisphosphonate treatment need to be evaluated in adults with CF.
329 Capillary blood gas sampling at annual assessment − a service
review
K. Pollard1, T.E. Daniels1, C. Etherington1, S.P. Conway1, M. Elliott2,
D.G. Peckham1. 1Leeds Teaching Hospital Trust, Adult Cystic Fibrosis Unit,
Leeds, United Kingdom; 2St James’s University Hospital, Respiratory Medicine,
Leeds, United Kingdom
Introduction: Following acquisition of appropriate equipment, and relevant train-
ing, capillary blood gas sampling (arterialized ear lobe sampling) was performed
on clinically stable patients with cystic ﬁbrosis (CF) at the time annual assessment,
The aim of this study was to assess the usefulness of this test, and to determine
whether we should continue to perform them routinely.
Method: Over 36 months, 173 capillary blood gas samples were undertaken in
148 adult patients with CF. Results were retrospectively collated onto a database
and categorized by a respiratory physician and physiotherapist according to normal
reference ranges. The diagnosis of acid base disorder was then conﬁrmed using the
Siggaard-Anderson acid base chart.
Results: See the table.
Number %
Normal 23 13
Hypoxia alone 72 42
all 123 71
Respiratory alkalosis 22 13
compensated 4 2
Metabolic acidosis 11 6
compensated 3 2
Metabolic alkalosis 2 1
compensated 12 7
Discussion: Capillary blood gas sampling has previously been shown to be compa-
rable to arterial sampling as long as a good technique is used. We were surprised
by the high prevalence of abnormal results in clinically stable patients. Further
work needs to be undertaken to better understand the causes, and implications of
abnormal metabolic results in patients with CF.
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Background: NBS for CF is relatively new in the UK compared to Australia. Few
studies have determined the nutritional status at diagnosis by NBS. The aim was to
assess nutritional status at diagnosis by NBS and again at 3 and 12 months of age.
Methods: All infants diagnosed with CF by NBS or with MI, between 2002–
2007, at the Royal Children’s Hospital, Melbourne, were included. Anthropometric
indices at birth, diagnosis, 3, and 12 months were evaluated and levels of fat soluble
vitamins A, D and E, at diagnosis and 12 months. Medications were determined
by chart review.
Results: 56 infants were included: NBS 44 (79%) or MI 12 (21%). Mean age at
diagnosis by NBS was 5.2 weeks. 47 (84%) infants were PI. At diagnosis, 9 (23%)
infants diagnosed by NBS and 2 (17%) MI infants had maintained their birth weight
percentile. At 3 months 19 (43%) in the NBS group and 2 (17%) in the MI group
had regained their birth weight percentile. By 12 months 27 (61%) NBS infants
and 5 (42%) MI infants regained their birth weight percentile. 44 (79%) infants
were deﬁcient in one of the fat soluble vitamins at diagnosis, vitamin A 23 (44%),
vitamin D 32 (67%), vitamin E 6 (12%). At 12 months, 9 (16%) were deﬁcient,
vitamin A 1 (2%), vitamin D 9 (20%) and vitamin E 4 (9%). All PI infants, and
2 PS infants had pancreatic enzyme replacement; 18 (32%) had acid suppressants;
51 (91%) used salt replacement; 29 (52%) commenced vitamin supplementation at
diagnosis and continued for 12 months.
Conclusion: Nutritional deﬁciencies are common at the time of diagnosis by NBS.
Nutritional parameters are signiﬁcantly improved around 12 months of age for most
babies diagnosed by NBS, but less often for babies with MI.
331 Birth weight, feeding practices and pancreatic enzyme
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Good nutrition is an essential part of CF care and is associated with improved
outcome. Newborn screening (NS) allows the opportunity to prevent nutritional
problems. National NS was introduced in the UK during 2007/8. Infants born at
our hospital have been screened for 30 years, 15 years using an IRT/DNA/IRT
protocol.
Methods: Feeding and PERT practices of 56 infants diagnosed by NS, between
January 2000 and December 2009 were prospectively recorded. Pancreatic insufﬁ-
ciency (PI) was conﬁrmed by faecal pancreatic elastase (FPE-1). Birth weight was
taken from newborn records. The incidence of symptomatic gastro-oesophageal
reﬂux (GOR) was documented.
Results: Of 56 infants (36M), 14 (25%) presented with meconium ileus (MI), 11 re-
quired surgery, 6 (11%) are pancreatic sufﬁcient (PS). 38 (68%) are homozygous
and 12 (21%) heterozygous (HZ) DF508, 4 are G551D HZ, 3 are R117H 7T HZ (all
PS) and 8 have other or no identiﬁable mutations. Median (range) age at diagnosis
(non MI infants) was 3.7 wks (0.9−7.3). Mean birth wt (range) of term infants
was M 3.1 kg (1.9−4.1), F 3.3 kg (2.8−4.4). 52 infants started PERT at diagnosis,
2 stopped following increasing FPE-1 values. At 3 mths the median (range) intake of
lipase/kg/day was 6431 IU (1096−19,500). 24 (43%) infants had symptomatic GOR
and were treated with thickened feeds and/or medical management. 19 were initially
breast fed, 5 stopped at diagnosis, 7 continued to 1 yr. 8 MI infants were given
a hydrolysed formula and 14 infants received a high energy formula, concentrated
formula or feed supplementation.
Discussion: Feeding and PERT requirements of NS infants are varied. Individu-
alised advice is an essential component of care.
